Nanobiotix Honored at the INVESTOR AWARDS 2013 in the "Young Talent" Category
11/8/2013 9:23:23 AM
Paris, France, 8 November, 2013 – NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today it has been awarded the “Young Talent” Award at the INVESTOR AWARDS 2013, referring to a newly listed company.
Nanobiotix was judged as the company, outside of the CAC 40, that achieved the most successful and most promising IPO of the year. The Company came first in this category for successfully meeting the main criteria: corporate profile, leadership in its business activity and financial health.
“It is an honor to receive this award from the Investor Awards panel,” said Laurent Levy, CEO and co-founder of Nanobiotix. “This award reflects the success of the Nanobiotix IPO in October 2012, where many investors showed an interest in our breakthrough technology in nanomedicine for local cancer treatment. We remain focused on the clinical development of our products, which positions us as a leader in nanomedicine. We are also preparing for the challenges around the marketing of our lead product, NBTXR3, which could occur in 2017.”
This prize was awarded by Boursorama and Morningstar that jointly organize the largest survey that selects listed companies by individual and professional investors’ preferences.
The online survey was conducted with investors by OpinionWay in May 2013. In total, more than 40,000 votes were collected (two-thirds of individuals and a third of professionals).
Next financial press release: revenue for the 3rd quarter of 2013 on November 14, 2013
About NANOBIOTIX - www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.
Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).
For more information, please contact:
Head of Communication
and Public Affairs
+33 (0)1 40 26 07 55
and investors relations
Louis-Victor Delouvrier / Emmanuel Huynh
+33 (0)1 44 71 98 53
Media relations (France)
Annie-Florence Loyer/ Nadège Le Lezec
+33 (0)1 53 63 27 27 / +33 (0)6 88 20 35 59
Media relations (Outside France)
Melanie Toyne Sewell / Donia Al Saffar
+44 (0) 207 457 2020
Help employers find you! Check out all the jobs and post your resume.
comments powered by